Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study
Authors:
Open Access
- 11 January 2024
- journal article
- research article
- Published by Taylor & Francis in Hematology
- Vol. 29 (1) , 2293579
Abstract
Multiple myeloma (MM) is a class of malignant plasma cell diseases. An increasing application of autologous stem cell transplantation (ASCT) and anti-myeloma agents represented by proteasome inhibitors (PIs) has improved the response rates and survival of MM patients. Patients progressing within 12 months were recently categorized with functional high-risk (FHR), which could not be clarified by existing genetic risk factors, with poor outcomes. Our study aimed to investigate clinical indices related to FHR and seek prognostic roles in transplant-eligible MM patients. Demographic and individual baseline clinical characteristics were compared by using the Pearson's chi-square and Mann-Whitney U test. Progression-free survival (PFS) and overall survival (OS) were described by Kaplan-Meier estimates and compared using the log-rank test. Logistic regression analysis was used to assess the association of baseline characteristics at MM diagnosis with FHR status. From 18th January 2010 to 1st December 2022, 216 patients were included and divided into two groups according to the FHR status. There was no difference in baseline data between the two groups. Renal impairment (RI, Scr > 2 mg/dL) was common in MM patients and made sense in FHR status. AST levels were validated as independent predictors for FHR status (p = 0.019). Patients with RI or higher AST levels (AST > 40 U/L) tended to have worse outcomes. However, transplants had apparently improved prognoses. Therefore, in the PIs era, transplantations are still effective therapies for transplant-eligible MM patients.Keywords
Funding Information
- National Natural Science Foundation (82270200, 82170189, 82070203, 81800194, 81770210)
- Key Research and Development Program of Shandong Province (2018CXGC1213)
- China Postdoctoral Science Foundation (2021T1404223)
- NCRCH (2021WWB02, 2020ZKMB01)
- Shandong Provincial Natural Science Foundation (ZR2021YQ51)
- Taishan Scholars Program of Shandong Province
- Shandong Provincial Engineering Research Center of Lymphoma
- Academic promotion programme of Shandong First Medical University (2019QL018)
This publication has 44 references indexed in Scilit:
- The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myelomaLeukemia, 2012
- A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple MyelomaImmune Network, 2012
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood, 2011
- Multiple MyelomaNew England Journal of Medicine, 2011
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cellsBlood, 2006
- Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working PartyJournal of Clinical Oncology, 2005
- Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myelomaLeukemia, 2004
- The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implicationsEuropean Journal of Cancer, 2004
- Magnitude of Response With Myeloma Frontline Therapy Does Not Predict Outcome: Importance of Time to Progression in Southwest Oncology Group Chemotherapy TrialsJournal of Clinical Oncology, 2004